See more : Murray International Trust PLC (MYI.L) Income Statement Analysis – Financial Results
Complete financial analysis of Eloxx Pharmaceuticals, Inc. (ELOX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Eloxx Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- bBreak Systems Company, Limited (3986.T) Income Statement Analysis – Financial Results
- King Fook Holdings Limited (0280.HK) Income Statement Analysis – Financial Results
- Orea Mining Corp. (OREAF) Income Statement Analysis – Financial Results
- Honyi International Company Limited (4530.TWO) Income Statement Analysis – Financial Results
- WeWork Inc. (WE) Income Statement Analysis – Financial Results
Eloxx Pharmaceuticals, Inc. (ELOX)
About Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 75.00K | 75.00K | 100.00K | 0.00 | 200.00K | 0.00 | 140.00K | 275.00K | 456.67K | 300.00K | 66.67K | 125.00K | 16.67K | 10.00K | 200.00K | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -18.71K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 75.00K | 75.00K | 100.00K | 0.00 | 200.00K | 0.00 | 140.00K | 275.00K | 456.67K | 300.00K | 66.67K | 125.00K | 16.67K | 10.00K | 200.00K | 1.00 | 18.71K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 1,871,400.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 23.73M | 45.57M | 14.59M | 26.35M | 20.49M | 16.40M | 733.66K | 2.18M | 4.57M | 3.34M | 2.09M | 2.57M | 3.72M | 2.64M | 2.35M | 1.76M | 1.21M | 1.57M | 1.42M | 1.15M | 793.90K | 370.19K | 479.47K | 476.46K | 173.46K | 0.00 | 0.00 |
| General & Administrative | 10.69M | 20.45M | 14.85M | 24.21M | 26.48M | 2.70M | 1.46M | 1.41M | 2.74M | 2.61M | 2.10M | 2.26M | 2.21M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.34M | 1.40M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 151.72K | 574.35K | 0.00 | 0.00 | 0.00 |
| SG&A | 10.69M | 20.45M | 14.85M | 24.21M | 26.48M | 2.70M | 1.46M | 1.41M | 2.74M | 2.61M | 2.10M | 2.26M | 2.21M | 2.35M | 2.21M | 2.29M | 2.41M | 1.92M | 2.03M | 2.91M | 1.48M | 1.94M | 1.49M | 1.97M | 982.40K | 0.00 | 0.00 |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -115.87K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -10.37K | -7.81K |
| Operating Expenses | 34.42M | 66.02M | 29.44M | 50.56M | 46.97M | 19.10M | 2.14M | 3.79M | 7.74M | 7.02M | 4.59M | 5.29M | 6.09M | 4.99M | 4.56M | 4.06M | 3.62M | 3.49M | 3.45M | 4.05M | 2.28M | 2.31M | 1.97M | 2.45M | 1.16M | -10.37K | -7.81K |
| Cost & Expenses | 34.42M | 66.02M | 29.44M | 50.56M | 46.97M | 19.10M | 2.14M | 3.79M | 7.74M | 7.02M | 4.59M | 5.29M | 6.09M | 4.99M | 4.56M | 4.06M | 3.62M | 3.49M | 3.45M | 4.05M | 2.28M | 2.31M | 1.97M | 2.45M | 1.16M | -10.37K | -7.81K |
| Interest Income | 274.00K | 8.00K | 337.00K | 1.07M | 601.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.48K | 0.00 | 0.00 | 43.08K | 100.45K | 69.30K | 0.00 | 54.03K | 0.00 | 0.00 | 24.26K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.95M | 1.26M | 1.41M | 1.62M | 7.00K | 43.00K | 265.20K | 533.00 | 2.77K | 77.44K | 119.09K | 134.55K | 88.12K | 610.67K | 1.01M | 434.15K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 695.00K | 960.00K | 571.00K | 559.00K | 216.00K | 39.00K | 44.08K | 93.39K | 177.07K | 349.66K | 293.63K | 258.02K | 143.27K | 126.57K | 111.75K | 96.85K | 166.17K | 40.11K | 43.72K | 30.42K | 38.70K | 24.36K | 24.16K | 18.71K | 4.00K | 0.00 | 0.00 |
| EBITDA | -33.37M | -66.02M | -33.46M | -50.56M | -46.15M | -20.39M | -4.59B | -8.85M | -17.88M | -8.80M | -4.65B | -4.83M | -6.33B | -4.72M | -4.17M | -3.50M | -3.15M | -3.38M | -3.28M | -4.01M | -2.23M | -2.09M | -1.95M | -2.43M | -1.15M | -10.37K | -7.81K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -4,827.52% | -9,982.48% | -6,572.38% | 0.00% | -2,491.85% | 0.00% | 2,290.26% | -1,343.62% | -620.45% | -1,051.61% | -5,068.89% | -2,853.45% | -25,703.22% | -23,608.61% | -1,120.21% | -200,724,000.00% | -242,873,500.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -34.42M | -66.02M | -33.46M | -50.56M | -47.57M | -20.39M | -4.59M | -11.19M | -18.08M | -9.15M | -4.65M | -5.41M | -7.92M | -4.85M | -4.28M | -3.60M | -3.32M | -3.42M | -3.32M | -4.04M | -2.27M | -2.11M | -1.97M | -2.45M | -1.16M | -10.37K | -7.81K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -14,926.64% | -24,102.31% | -9,147.80% | 0.00% | -2,705.76% | 0.00% | -3,461.80% | -1,558.07% | -788.11% | -1,107.00% | -5,129.06% | -2,657.39% | -24,223.34% | -22,686.06% | -1,057.12% | -197,107,000.00% | -244,744,800.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.65M | -709.00K | -1.12M | -319.00K | 502.00K | -824.00K | -2.24M | 2.25M | 12.95K | -77.44K | -1.47M | 345.40K | 649.73K | 4.85M | 4.28M | 3.60M | 3.32M | 3.42M | 1.13M | 959.02K | 130.95K | 150.55K | 60.33K | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -36.07M | -66.73M | -34.58M | -50.87M | -47.06M | -21.21M | -6.84M | -8.95M | -18.06M | -9.23M | -6.12M | -5.07M | -7.27M | -12.77M | -4.76M | -4.27M | 0.00 | 0.00 | -3.03M | -3.76M | -2.14M | -1.96M | -1.91M | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -11,930.57% | -24,085.05% | -9,225.23% | 0.00% | -2,533.07% | 0.00% | -9,123.46% | -1,731.89% | -934.55% | 0.00% | 0.00% | -2,426.36% | -22,560.92% | -21,376.54% | -981.84% | -191,073,900.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 1.26M | 1.41M | 1.62M | 122.00K | 43.00K | -1.04M | -680.00K | 2.77K | 77.44K | 119.09K | -24.26K | 1.07M | 8.54M | 1.44M | 1.00M | -69.30K | -104.46K | -342.82K | -310.35K | -202.27K | -174.81K | -94.08K | -2.53K | 13.14K | 10.37K | 7.81K |
| Net Income | -36.07M | -66.73M | -34.58M | -50.87M | -47.19M | -21.21M | -5.80M | -8.27M | -18.06M | -9.23M | -6.12M | -5.07M | -7.27M | -13.38M | -5.73M | -4.60M | -3.25M | -3.31M | -2.98M | -3.73M | -2.07M | -1.94M | -1.88M | -2.44M | -1.17M | -10.37K | -7.81K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -11,023.91% | -24,085.05% | -9,225.23% | 0.00% | -2,533.07% | 0.00% | -9,559.65% | -2,082.50% | -1,007.62% | -1,083.90% | -4,972.38% | -2,383.13% | -22,361.26% | -20,663.38% | -969.71% | -187,699,100.00% | -244,491,600.00% | 0.00% | 0.00% | 0.00% |
| EPS | -16.65 | -38.15 | -34.47 | -53.46 | -58.19 | -170.52 | -199.71 | -325.47 | -1.00K | -1.35K | -3.59K | -4.73K | -7.48K | -21.38K | -23.19K | -20.18K | -14.92K | -17.18K | -15.43K | -21.80K | -13.96K | -13.10K | -19.15K | -24.95K | -655.27 | -134.73 | -101.43 |
| EPS Diluted | -16.65 | -38.15 | -34.47 | -53.46 | -58.19 | -170.52 | -199.71 | -325.47 | -1.00K | -1.35K | -3.59K | -4.73K | -7.48K | -21.38K | -23.19K | -20.18K | -14.92K | -17.18K | -15.43K | -21.80K | -13.96K | -13.10K | -19.15K | -24.95K | -655.27 | -134.73 | -101.43 |
| Weighted Avg Shares Out | 2.17M | 1.75M | 1.00M | 951.58K | 810.91K | 124.41K | 29.02K | 25.40K | 18.02K | 6.85K | 1.71K | 1.07K | 972.00 | 626.00 | 247.00 | 228.00 | 218.00 | 193.00 | 193.00 | 171.00 | 148.00 | 148.00 | 98.00 | 98.00 | 1.78K | 77.00 | 77.00 |
| Weighted Avg Shares Out (Dil) | 2.17M | 1.75M | 1.00M | 951.58K | 810.91K | 124.41K | 29.02K | 25.40K | 18.02K | 6.85K | 1.71K | 1.07K | 972.00 | 626.00 | 247.00 | 228.00 | 218.00 | 193.00 | 193.00 | 171.00 | 148.00 | 148.00 | 98.00 | 98.00 | 1.78K | 77.00 | 77.00 |
Eloxx (ELOX) Down After Cystic Fibrosis Study Fails to Meet Goal
Eloxx Pharmaceuticals' (ELOX) phase II combination study evaluating pipeline candidate ELX-02 in cystic fibrosis fails to achieve statistical significance in efficacy endpoints.
Popular Penny Stocks to Add to Your Watchlist Right Now
Check these three penny stocks out for your list right now The post Popular Penny Stocks to Add to Your Watchlist Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Read Why Eloxx Pharma Stock Continues To Fall
H.C. Wainwright lowered the price target on Eloxx Pharmaceuticals Inc (NASDAQ: ELOX) to $1 from $2 and reiterated a Neutral rating. Analyst Andrew Fein says the ELX-02 top-line data "raises more questions than answers.
Eloxx Pharmaceuticals to Host Investor and Analyst Call and Webcast on Cystic Fibrosis Programs
Globally renowned CF Expert, Dr. Eitan Kerem will provide key insights
ELOX Stock: Why It Increased Today
The stock price of Eloxx Pharmaceuticals Inc (NASDAQ: ELOX) significantly increased today. This is why it happened.
New Strong Sell Stocks for August 24th
BGS, FTHM, NTLA, LEVL, and ELOX have been added to the Zacks Rank #5 (Strong Sell) List on August 24, 2021
Eloxx Pharmaceuticals Reports Second Quarter 2021 Financial and Operating Results and Provides Business Update
Added Additional Treatment Arm and Provided Enrollment Update for Ongoing ELX-02 Phase 2 Clinical Trials for Cystic Fibrosis (CF)
Hemogenyx Pharmaceuticals PLC Announces Appointment of Business Advisor & Board Observer
Dr Alan E. Walts joins Hemogenyx Pharmaceuticals team; renowned business leader brings industry experience in corporate and private venture capital, business development, R&D and general management. LONDON, UK / ACCESSWIRE / July 26, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the...
Eloxx Pharmaceuticals Provides Enrollment Update for Ongoing Phase 2 Clinical Studies for Cystic Fibrosis
Data Readout for First Four Treatment Arms Expected in the Fourth Quarter of 2021 Data Readout for First Four Treatment Arms Expected in the Fourth Quarter of 2021
7 Reddit Penny Stocks to Watch For the Long Weekend
With July 4th on the way, which penny stocks are you watching right now? The post 7 Reddit Penny Stocks to Watch For the Long Weekend appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Source: https://incomestatements.info
Category: Stock Reports